HYPD NASDAQ
Hyperion DeFi, Inc.
1W: -7.7%
1M: +21.9%
3M: +14.4%
YTD: +4.2%
1Y: -62.5%
$3.73
+0.07 (+1.91%)
Weekly Expected Move ±11.7%
$3
$3
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
15 relationships15
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-09-15
Earliest Filing
2025-10-31
Latest Filing
partner: 13
licensee: 2
Counterparties (Filed by HYPD)
15 relationshipsCompanies named in HYPD's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Kinetiq Research Pte. Ltd. | — | partner | Joint Validator Operators' Agreement for co-branded validator node on Hyperliquid | 2025-10-31 | View |
| Pier Two Pty Ltd | — | partner | Joint Validator Operators' Agreement for infrastructure hosting and management | 2025-10-31 | View |
| Felix Foundation | — | partner | HAUS Agreement to support deployment of perpetual futures market on Hyperliquid | 2025-10-31 | View |
| Chardan Capital Markets, LLC | — | partner | Entered into Amendment No. 1 to the Amended and Restated Sales Agreement to increase the aggregate offering price from $ | 2025-09-24 | View |
| Chardan Capital Markets LLC | — | partner | Placement agent for the Private Placement. | 2025-06-24 | View |
| Chardan Capital Markets, LLC | — | partner | Underwriter for the at-the-market offering program. | 2025-02-24 | View |
| Chardan Capital Markets, LLC | — | partner | Sales agent for the Company's at-the-market offering program | 2024-12-30 | View |
| Leerink Partners | — | partner | Previous sales agent whose agreement was amended and replaced by Chardan | 2024-12-30 | View |
| Chardan Capital Markets, LLC | — | partner | Placement agent engaged for the registered direct offering. | 2024-12-09 | View |
| Bausch Health Companies Inc. | BHC | partner | Original licensee of MicroPine prior to spinoff and assignment | 2024-01-16 | View |
| Bausch Health Ireland Limited | — | partner | Wholly owned subsidiary of Bausch Health that originally held the license | 2024-01-16 | View |
| Bausch + Lomb Ireland Limited | BLCO | partner | Acquired the license from Bausch Health and entered into Letter Agreement to reacquire rights to MicroPine | 2024-01-16 | View |
| Formosa Pharmaceuticals, Inc. | — | partner | Eyenvia entered into a license agreement granting an exclusive sublicensable license to commercialize a novel Clobetasol | 2023-08-16 | View |
| Arctic Vision (Hong Kong) Limited | — | licensee | Granted exclusive rights to research, develop, manufacture, and commercialize MydCombi in Greater China and South Korea. | 2021-09-15 | View |
| Senju Pharmaceutical Co., Ltd. | — | licensee | Excluded from the territory covered by the license granted to Arctic Vision in exchange for additional payments. | 2021-09-15 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-02 | Termination of Agreement; Earnings Release; Regulation FD; Other Events; Exhibits | View | |
| 2026-08-12 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-07-08 | Officer/Director Change; Exhibits | View | |
| 2026-07-01 | Shareholder Vote; Exhibits | View | |
| 2026-06-05 | Other Events; Exhibits | View | |
| 2026-05-14 | Earnings Release; Regulation FD; Other Events; Exhibits | View | |
| 2026-03-26 | Earnings Release; Bylaws Amendment; Regulation FD; Exhibits | View | |
| 2026-01-05 | Unregistered Sales of Equity Securities; Departure/Election of Directors; Appointment of Officers; R | View | |
| 2025-12-10 | Other Events | View | |
| 2025-11-17 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-11-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-10-31 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers; | Agreement | View |
| 2025-10-02 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-09-29 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-09-24 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-09-08 | Notice of Delisting or Transfer; Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-21 | Material Modification to Rights of Security Holders; Submission of Matters to a Vote of Security Hol | View | |
| 2025-08-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-02 | Departure/Election of Directors; Appointment of Officers; Amendments to Articles of Incorporation or | View | |
| 2025-06-27 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR